Nanoplatforms for Delivery of Inhibitors and Biologics
The nanoparticle formulation:ΓÇóInvolves use of biocompatible componentsΓÇóEffectively minimizes toxicity of individual componentsΓÇóMaximizes accumulation of therapeutic agents at the diseased siteΓÇóIs highly injectable as compared to existing formulationsΓÇóIs capable of being used as a mono-therapy or a dual drug deliveryΓÇóIs designed to target a tumor using passive or active methodsΓÇóIs further capable of being used in combination with chemo and radio therapiesΓÇóHas an increased bioavailability as compared to conventional platformsΓÇóWould be commercially useful for treatment of various indications such as cancer, neurological disorders, traumatic brain injuries, CNS disorders, inflammation, urinary tract disorders, and respiratory system disorders
None
USA

